***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: Fursultiamine ( TTFD ) , a derivative of thiamine , at an oral dose of 100 mg/day had a mild beneficial effect in patients with Alzheimer 's disease in a 12-week open trial . The improvement could be observed not only in their emotional or other mental symptoms but also in intellectual function . Only mildly impaired subjects showed cognitive improvement . Alzheimer patients '  blood levels of thiamine  before the trial were within the normal range . No adverse reactions were observed and all patients tolerated the trial well . TTFD could afford an alternate treatment to large doses of thiamine hydrochloride in Alzheimer patients . However , further investigations of the therapeutic implication s of thiamine and its possible etiologic clues to Alzheimer 's disease are necessary Because a previous short-term study demonstrated a statistically significant , but not clinical ly important , improvement in cognitive test scores during thiamine treatment in patients with dementia of the Alzheimer 's type , a 12-month , double-blind , parallel-group study was conducted to examine whether long-term administration of thiamine at 3 g/d might slow the progression of dementia of the Alzheimer 's type . Fifteen subjects were enrolled and 10 completed the 1-year study . Data are available for two additional subjects through the first 9 months of study . No significant differences were found between the placebo and thiamine groups at any point during the study . In both groups , overall means for the Mini-Mental State Examination , verbal learning , and naming scores decreased significantly over the 12-month study period . These results do not support the hypothesis that long-term administration of thiamine at 3 g/d might slow the progression of dementia of the Alzheimer 's type Thiamine is important not only in the metabolism of acetylcholine but also in its release from the presynaptic neuron . Pathologic , clinical , and biochemical data suggest that thiamine deficiency is detrimental to the cholinergic system and that thiamine-dependent enzymes may be altered in Alzheimer 's disease . Two previous studies reported contradictory results in patients with dementia of Alzheimer 's type treated with 3 g/day of thiamine . In the present study , we examined the effects of 3 to 8 g/day thiamine administered orally . Our results suggest that thiamine at these pharmacologic dosages may have a mild beneficial effect in dementia of Alzheimer 's type . The mechanism of the observed effect is unknown , but the findings warrant further investigation , not only for their therapeutic implication s but for their possible etiologic clues . In addition , the results suggest long-term carry-over effects that should be considered in the design of future studies As a test of the significance of previously described biochemical abnormalities in thiamine-dependent enzymes in brains and other tissues in patients with Alzheimer 's disease , a double-blind , placebo-controlled , crossover , outpatient pilot study compared the effects of 3 g/d of oral thiamine hydrochloride for three months with those of a niacinamide placebo .  Eleven moderately impaired patients with " probable Alzheimer 's disease " by the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer 's Disease and Related Disorders Association criteria completed the study . All patients were well nourished and had no stigmata of dietary thiamine deficiency . Their initial mean + /- SEM Mini-Mental State Examination score was 14.2 + /- 1.4 , and the mean age was 72 years .  Global cognitive rating by the Mini-Mental State Examination was higher during three months with 3 g/d of oral thiamine hydrochloride than with niacinamide placebo .  Behavioral ratings , however , did not differ significantly , nor did clinical state when it was judged subjectively 
    Output:
    
The data were compatible with thiamine producing harm , no change or improvement .
There was no statistically significant difference in the test of Verbal Fluency and the Boston Naming Test .
REVIEW ER 'S CONCLUSIONS This review finds no evidence that thiamine is a useful treatment for the symptoms of Alzheimer 's disease .
Thiamine can not be recommended for patients with Alzheimer 's disease